Safety assessments indicated that gastrointestinal adverse functions, principally nausea and diarrhea, had been dose-dependent but usually mild and transient. These conclusions set up the therapeutic window and educated dose variety for subsequent Period 3 trials.Renal elimination of unchanged orforglipron is nominal, with excretion happening large